|
Back to Home » May 2020 News » Targovax Announces That the ONCOS-102 and Durvalumab Abstract is Selected for a Poster Discussion Session at ASCO |
Targovax Announces That the ONCOS-102 and Durvalumab Abstract is Selected for a Poster Discussion Session at ASCO |
May 14, 2020
OSLO, Norway, May 14, 2020 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that an abstract relating to the dose escalation part of the ONCOS-102 and durvalumab trial in...
Source URL: https://www.prnewswire.com:443/news-releases/targovax-announces-that-the-oncos-102-and-durvalumab-abstract-is-selected-for-a-poster-discussion-session-at-asco-301059127.html
|
|
|
|
